Over the immediate past 4 years, our program has collected hematopoietic progenitor cells by apheresis from 48 individuals aged 61 and over (range 61-71 years of age). We have retrospectively analyzed the collection and transplant results associated with employing these donors, and have compared them with 175 donors aged 60 or less who were collected during the same time period. We have found no significant difference in venous access (P ¼ 0.208), rate of post-transplant engraftment of neutrophils (P ¼ 0.117) and platelets (P ¼ 0.692), or in rate and grade of acute GVHD (P ¼ 0.806). However, we have found that these older donors have a significantly lower mobilization of CD34 þ cells as reflected in lower absolute counts of circulating CD34 þ cells preapheresis (P ¼ 0.016). This, in turn, results in lower CD34 þ cell yields in apheresis products (Po0.001), trending towards requiring more apheresis procedures (22.9 vs 13.7%, P ¼ 0.095) to collect sufficient CD34 þ cells for transplantation. We conclude that it is practical when necessary to employ donors aged 60 and above, as well as safe for both donor and intended recipient. However, concern over reduced CD34 þ cell mobilization may be sufficient grounds to seek younger donors when possible.
INTRODUCTION
There is a reluctance to attempt collection of hematopoietic progenitor cells (HPC) for allogeneic transplant from donors beyond the age of 60, particularly for unrelated transplants. 1 Notably, it is the policy of the National Marrow Donor Program that potential donors must be no older than 60 years of age. 2 This is due to concerns regarding age-associated frailty, potential for poor mobilization 3 risk of reduced potential for timely and complete engraftment, 4 and increased risk of high-grade acute GVHD. 1 In recent years, as many of the diseases for which allogeneic HPC transplantation is indicated are associated with advancing age; this therapy has been increasingly offered to patients in their sixth or greater decade of life. 5 As a result, the age of sibling donors has also increased, and donors beyond the age of 60 years have been used and their cells have been transplanted. Within our own program, we have collected HPC from 223 sibling donors between 1 January 2008 and 31 December 2011, 48 (21.5%) of whom have been of age 61 or above at the time of G-CSF mobilization and apheresis collection. Here we report a retrospective analysis of mobilization and collection effort required, apheresis complications, post-transplant engraftment and GVHD, comparing donors aged 61 years and beyond to their younger counterparts.
MATERIALS AND METHODS

Donors, screening and pre-collection preparation
The analysis reported here was done under approval of the University of South Florida Institutional Review Board, using de-identified source data already collected in the clinical conduct of the Blood and Marrow Transplant service at the H. Lee Moffitt Cancer Center.
Donors were selected on the basis of being siblings of transplant candidates who possess matching HLA typing. Donors were cleared for donation following infectious disease marker testing, and a detailed history and physical examination to determine possible risk factors for undergoing apheresis collection. There is no record of any prospective donors, of any age, being rejected for donation due to physical status considerations.
The 223 donors (175 aged less than 61, 48 aged 61 or greater) included in this retrospective analysis accounted for 257 actual collections (198 collections from donors aged o61 and 59 collections from donors aged X61) (Table 1) . A total of 206 collections (156 from donors agedo61 and 50 from donors aged X61) were performed using antecubitally placed 16 or 18 gauge needles (Table 2) . Venous access catheters, when required, were placed by a team of dedicated mid-level practitioners, and placement was confirmed before initiation of the apheresis process.
Mobilization for HPC collection was by daily administration of 10 mcg/kg of filgrastim, starting 4 days before the scheduled apheresis collection. Filgrastim administration was by s.c., performed by the Moffitt Cancer Center Blood and Marrow Transplant Program nursing staff, at approximately 1900 h every evening, that is, 12 h before the presentation for apheresis. Daily G-CSF administration was continued until the target CD34 dose of 5-10 million per recipient kilogram was achieved.
Apheresis
Collection was performed using Cobe Spectra apheresis instruments (Terumo BCT, Lakewood, CO, USA). The mononuclear collection protocol that is built in to the instrument (version 6.1) was employed for all collections, along with the manufacturer's corresponding leukocyte collection set. Anti-coagulation was effected with a mix of ACD-A (Fenwal Inc., Lake Zurich, IL, USA) supplemented with 1000 U heparin (Sagent, Schaumburg, IL, USA) per liter. This mixture was introduced to the apheresis draw line at a ratio of 1 part anticoagulant to 25 parts blood drawn.
Blood withdrawal was done at the highest rate consistent with donor comfort and safety, but not exceeding a rate of 100 ml/min. Using a colorimetric scale provided by the manufacturer, the cell interface within the apheresis instrument's centrifuge was adjusted to achieve an output product with a hematocrit of approximately 3%. The output was monitored at least every 30 min during collection, and more frequently if the 1 Department of Blood and Marrow Transplant, H. Lee Moffitt Cancer Center, Tampa, FL, USA and hematocrit was observed to drift, or in case of any circumstances that might affect the interface, such as significant change in donor position or instrument pressure alarms.
After one donor body blood volume had been apheresed, a 0.5-ml sample was aseptically withdrawn from the collection bag using a sampling site coupler inserted into one of the bag's available spike ports. This sample was used to assess the number of CD34-positive cells that had been collected at that point in the collection, and to project the total blood volume to apherese to achieve a final CD34 count of between 5 and 10 million per kg of recipient body weight. This method of determining collection volume has been validated to be accurate across all CD34 cell concentrations documented in this report. 6 No collection was allowed to exceed six total body blood volumes.
Although there were recipient to donor weight discrepancies seen in both the under 61 and the 61 and above donor groups, the recipient to donor weight ratios for both groups are statistically identical (Table 1) .
Cell counts and CD34 assessment
Total leukocyte counts were obtained using a Sysmex K-21 cell analyzer (Sysmex America, Mundelein, IL, USA). CD34 analysis was performed using a Becton-Dickinson FACS-Calibur flow cytometer (Becton-Dickinson, San Jose, CA, USA) and the method that has been advanced by Sutherland and colleagues 7, 8 ('ISHAGE double platform method'). Our laboratory bench marks our use of this method by continually meeting passing criteria for the College of American Pathologists (Northfield, IL, USA) semi-annual proficiency test for CD34 enumeration.
Cell counts and CD34 data were entered into the Cell Therapies Facility database (StemLab, StemSoft Software, Vancouver, BC, Canada) for subsequent reporting and statistical analysis.
Donor and patient performance tracking
Apheresis adverse events were entered into the StemLab database (StemSoft) in real time, that is, while the apheresis donor was in the care of the apheresis staff. Because grade 2 citrate-driven hypocalcemia reactions are ubiquitous for the volumes of apheresis processing that are routinely done, and because recording of these lowgrade reactions was highly inconsistent primarily due to the relative tolerance of different donors, we discontinued recording these reactions in the database and only track serious, namely grade 3 or greater, adverse reactions. These were characterized by grades and by systems, such as neuromuscular, cardio-pulmonary, or gastrointestinal. The specific symptoms/complaints were also entered along with follow-up actions and resolutions.
Transplant outcome data were recorded in the Moffitt Cancer Center Blood and Marrow Transplant Program database (BMTServe, StemSoft, Inc.) for subsequent reporting and statistical analysis. Data were entered into this database by trained data abstracters. Dates of post-transplant engraftment were assigned as the first day of three consecutive days, wherein neutrophil counts remained above 500 per ml, and the first day of five consecutive days wherein platelet counts remained above 20 000 per ml without transfusional support. Overall GVHD grading was assigned according to a pre-established paradigm to combine physician scoring separately of skin, gastrointestinal and liver specific GVHD. Specifically, if skin GVHD was a grade 1 or 2, with no gut or liver involvement, overall grade would be I. If skin GVHD was graded at 3, or gut or liver were grade 1, the overall grade would be II. If skin was grade 3, and gut or liver were grade 2-3, then the overall grade would be III. If any tissue system was graded at 4, then the overall GVHD grade would be IV.
Statistical analysis
Donors were grouped for retrospective analysis according to their age at the time of mobilization treatment and HPC apheresis collection. The age distribution of the donors, as well as the N for each group (175 aged 60 or less, 48 aged 61 or greater), gender distribution, weights and the fraction in each group requiring multiple collections are shown in Table 1 .
Data were compiled from the database using Crystal Reports (SAP America, Newtown Square, PA, USA) and transferred into Excel (Microsoft Corporation, Redmond, WA, USA) spreadsheets. Statistical analysis was performed directly from the spreadsheets using the IBM SPSS statistics 20 package (IBM Corporation, Armonk, NY, USA). In respect of the substantially different group sizes and concomitant variability, continuous variable data were analyzed using the Mann-Whitney U-test. Tabular data were analyzed using a Pearson's w 2 -statistic. Engraftment data were compiled according to days post transplant for recovery of neutrophils to 500 per mm 3 and recovery of platelets to 20 000 per mm 3 , along with a censoring variable to indicate individuals whose engraftment was incomplete. The engraftment data were analyzed using the Mantel-Cox log-rank test of comparative survival.
Continuous variable results are reported throughout this report as mean ± s.d. No statistical inference should be inferred from this, but rather an indication of approximate central point and variability of specific measures. Allogeneic HPC donors aged greater than 60 years WE Janssen et al
RESULTS
Circulating CD34 þ cells and multiple collections
Before each apheresis procedure, a blood sample was obtained from the donor, and the circulating CD34 cell concentration was determined. It can be observed in Figure 1 that the older donors trend to having lower circulating CD34 counts per mL than do those donors below the age of 61. This reaches the level of statistical significance with a Mann-Whitney U-test, P ¼ 0.016.
Although not reaching the level of statistical significance (w 2 , P ¼ 0.095), the percentage of older donors requiring multiple apheresis collections to reach target CD34 dosing (22.9%) trended higher than was the case for the donors below the age of 61 (13.7%) ( Table 1 ). This trend did not coincide with the donor WBC or Hct, with the liters of blood apheresed (Table 2) , nor with the efficiency of CD34 cell collection (Table 3) .
Apheresis products obtained-quality, yields, efficiency The qualities of apheresis products obtained both from donors aged 60 or less, and obtained from donors aged 61 or greater were generally similar (Table 3) . A notable exception to this is the hematocrit of the products, which trended lower in products collected from the older donors (2.81 ± 0.97%) compared with products collected from the donors aged 60 or less (2.95 ± 0.75). By Mann-Whitney U-test, this difference is significant (P ¼ 0.020).
CD34 þ cell yields in the apheresis products were significantly lower (Mann-Whitney U-test, Po0.001) in products collected from donors aged 61 years and greater (418 ± 224 million CD34 þ cells) than in products collected from donors aged 60 years or less (570±249 million CD34 þ cells) (Figure 2 ). This difference does not coincide with the CD34 þ collection efficiencies, computed as product CD34 yield divided by the product of circulating CD34 þ cells and blood volume apheresed, which were associated with each product (Figure 3 ).
Catheter requirements and adverse events during leukopheresis procedures The percentage of donors requiring catheters to complete collection is given in Table 2 . Although hypothetically it would be expected that older donors might have greater difficulties with venous access due to reduced vein elasticity, in fact, fewer of the donors aged 61 years or greater actually required indwelling venous access catheters, though this was not statistically significant (P ¼ 0.208).
As noted in the methods section, our apheresis adverse event tracking is limited to serious reactions, namely grade 3 or above. Within the 257 individual collections reported herein, only 3 such reactions were recorded, preventing statistical analysis. Moreover, all three such reactions occurred in donors aged less than 61 years. The reactions that were recorded included myalgia, paresthesia followed by syncope, and non-specific chest pain. Total CD34 yield in apheresis product Figure 2 . Total CD34 þ cell yield in apheresis product: Apheresis products were sampled immediately upon transfer to cell processing laboratory. Total WBC and CD34 cells were enumerated. Box and whisker representation: solid line within box represents median total CD34 count (556.5E þ 6 for products obtained from donors aged less than 61 years, and 454.8E þ 6 for products obtained from donors aged 61 or greater), box represents inner two quartiles, and whiskers represent the lesser of minimum-maximum spread, or ±1.5 times the breadth of the inner quartile range. Values outside 1.5 times the inner quartile range are represented as points, labeled with their CD34 þ count value (times 1E þ 6). Mann-Whitney U-test, Po0.001. Immediately following transfer of collected products to the processing laboratory, samples were taken and the products cellularity, Hct and CD34 collection efficiency was assessed. Results are reported as mean±s.d. P-values are derived from Mann-Whitney U-statistic.
Post-transplant follow-up-engraftment and GVHD To determine if cells obtained from older donors might result in delayed engraftment, neutrophil and platelet recoveries for recipients transplanted from both age groups were analyzed using the Kaplan-Meier approach ( Figure 4 ) and the Mantel-Cox log-rank statistic. Neutrophil engraftment (median recovery for both groups, 16 days) and platelet engraftment (median recovery for both groups, 16 days) were not different between the patients transplanted with cells obtained from donors aged 60 or less, and those transplanted with cells obtained from donors aged 61 or greater (neutrophil, P ¼ 0.117; platelet, P ¼ 0.692).
Acute GVHD incidence and grade within the first 100 days post transplant were compared in a tabular fashion (Table 4 ). The greatest incidence of acute GVHD was grade II, with the proportion of this grade approximately equal between the two groups (53.1% in patients receiving grafts from donors aged below 61, and 50.0% in patients receiving grafts from donors aged 61 or greater). There was an apparent slightly greater incidence of grade III acute GVHD in patients receiving grafts from donors aged 61 or greater (18.8% compared with 13.1%), but the overall statistical assessment indicates no difference (P ¼ 0.806). No acute GVHD grade was assigned to 13.8% of patients transplanted from donors aged 60 or less, nor to 8.3% of patients transplanted from donors aged 61 or above. Reasons for non-grading are not recorded, but are known to include death before grade assignment, charting ambiguities and too little elapsed time post transplant.
To determine if a difference in acute GVHD should be anticipated based on numbers of transplanted T-lymphocytes, the total number of CD3 þ cells collected between the younger and older donors was compared ( Figure 5 ). In spite of several high outlier CD3 þ cell counts and an apparent overall trend to higher CD3 þ counts in products collected from donors aged less than 61, there was no demonstrable difference between the two groups with respect to CD3 þ cell yield from apheresis (P ¼ 0.089). CD34 Apheresis collection efficiency Figure 3 . Apheresis collection efficiency: approximate number of CD34 cells processed in apheresis was computed as circulating CD34 cells/mL Â mL of whole blood processed in apheresis. Efficiency was computed as total number of CD34 cells in product, divided by approximate CD34 cells processed in apheresis, multiplied by 100. Box and whisker representation: solid line within box represents median collection efficiency (46.0% for donors aged less than 61 years, and 41.3% for donors aged 61 or greater), box represents inner two quartiles, and whiskers represent the lesser of minimum-maximum spread, or ±1.5 times the breadth of the inner quartile range. Values outside 1.5 times the inner quartile range are represented as points, labeled with their percent efficiency values. Mann-Whitney U-test, P ¼ 0.116. 
DISCUSSION
The reported reluctance to employ donors of HPC for allogeneic transplant, who are aged above 60 is predicated primarily on three concerns. 1, 3, 4 These are: (i) frailty of donors and associated risk for adverse outcomes from collecting HPC from these individuals; (ii) reduced HPC numbers and function, creating risk of poor engraftment when grafts from these individuals are used; and (iii) elevated risk of GVHD in the recipients of grafts obtained from the older donors. To this, we would add a concern for an increased need for indwelling catheters to access venous blood.
We have reported here the collection and transplant experience from a group of 48 donors of HPC, who were aged 61 and above (range 61-71) at the time of their apheresis HPC collection. In our analysis, we have been unable to demonstrate an increased risk of serious apheresis-associated adverse events or increased need for indwelling catheters to achieve apheresis collection. Similarly, we have been unable to demonstrate that transplantation using HPC products collected from donors aged 61 and above result in increased risk of acute GVHD or potential for GVHD as reflected in collected lymphocyte load, or in a delay of engraftment of either neutrophils or platelets. We do not, however, have sufficient data to demonstrate long-term stability of grafts collected from older donors, and the hypothetical possibility that HPC from such donors may fail over time must still be taken into consideration.
We have found that when compared with a younger cohort of donors, aged 60 or less, the donors aged 61 or more do not, as a group, mobilize CD34 þ cells as well. This was reflected in circulating CD34 þ cell counts per mL of 75.4 ± 47.9 (mean ± s.d.) among the 60-year-old and below donors, but only 59.1 ± 43.3 per mL among the 61-year-old and above donors (P ¼ 0.016, Figure 1 ). This reduced level of circulating CD34 þ cells coincides in our analysis with a lower yield of CD34 þ cells in the collected apheresis product (Po0.001, Figure 2 ), which cannot be accounted for by reduced efficiency of collection of CD34 þ cells (Figure 3) .
We have identified a reduced Hct in the apheresis products collected from donors aged 61 and above (P ¼ 0.020, Table 3 ). This observation defies immediate explanation, as our hemapheresis operators consistently set the Spectra instruments to deliver a product Hct of approximately 3. It is possible that this reduced collection of erythrocytes could contribute to the reduced CD34 þ yield, as the lowest density erythrocytes and the highest density mononuclear cells may co-mingle in the density bands within the apheresis instrument's centrifuge. However, the circulating CD34 þ cell concentration was reduced before apheresis was initiated, suggesting that the reduced product Hct cannot be the sole cause for the observed CD34 þ yields.
Though not statistically significant, the reduced levels of circulating CD34 þ cells in older donors, and the corresponding reduced yield of CD34 cells in the final apheresis products, appear to drive an increased need to perform more than one apheresis collection to obtain needed CD34 þ doses, with 22.9% of older donors requiring multiple collections compared with only 13.7% of the 60-year-old and younger donors having to be harvested more than once. This cannot be attributed to differences in donor gender, weight, recipient to donor weight disparities (Table 1) , or collection efficiency (Figure 3) .
The age at which individuals are considered candidates for allogeneic transplant has increased in recent years. With the increase in recipient age, there is an associated increase in the age of sibling donors. We have analyzed several aspects of apheresis collection and transplant that may represent potential problems to be encountered in employing donors aged 61 and above. We submit that our analysis supports the feasibility and safety, for both donor and recipient, to mobilize and collect apheresis HPC from individuals aged beyond 60 years. Our analysis raises the caution, however, that donors aged beyond 60 do not respond as well to the G-CSF mobilization, and may as a result, require more apheresis procedures to collect sufficient cells for transplant, with the concomitant added risk associated with each additional procedure. Our analysis does not, and cannot, address the possibility that reduced mobilization may be reflective of declining hematopoietic potential, which hypothetically could be reflected in long-term graft instability. We would certainly advocate that, given a choice, a younger donor would be superior. However, given our results, we would also advocate that a patient not be denied an allogeneic transplant if the only suitable donor is aged 61 or beyond. 
